Block Listing Six Monthly Return

RNS Number : 8859Y

Alliance Pharma PLC

06 January 2020

 

For immediate release

6 January 2020

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Listing Six Monthly Return

Name of applicant:		ALLIANCE PHARMA PLC
Names of schemes:		a)     The Alliance Pharma plc Approved Share Option Plan 2005 b)    The Alliance Pharma plc Share Option Plan 2006 c)     The Alliance Pharma plc Company Share Option Plan 2015
Period of return:	From:	28 June 2019	To:	28 December 2019
Number of securities originally admitted at date of admission:		25,000,000 ordinary shares of 1p each 28 June 2017
Balance of unallotted securities under schemes from previous return:		a)     983,541 b)    15,345,688 a)     1,226,097
Plus:  The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):		a)     Nil b)    Nil c)     Nil
Less:  Number of securities issued/allotted under schemes during period:		a)     434,467 b)    9,234,354 c)     588,621
Equals:  Balance under schemes not yet issued/allotted at end of period:		a)     549,074 b)    6,111,334 c)     637,576

Name of contact:	Chris Chrysanthou, Company Secretary
Telephone number of contact:	Tel. [phone]

For further information:

Buchanan                                                                                                        + 44 (0) 20 7466 5000

Mark Court / Hannah Ratcliff

Numis Securities Limited                                                                              + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

Corporate Broking: James Black

Investec Bank plc                                                                                           [phone]

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

BLRKKABPNBKDADK